Table 7.
BALF immunopathology biomarkers of severely affected lung on mortality status.
| Biomarkers | Survivors (n = 6) | Non-survivors (n = 22) | p |
|---|---|---|---|
| sTREM (ng/mg protein), median (IQR) | 1.26 (0.3–3.71) | 1.17 (0.37–10.72) | .780 |
| Alveolar macrophage | |||
| % (Macrophage cells/CD45+, HLA-DR+, CD11b+), mean (±SD) | 8.7 (±7.59) | 6.8 (±4.28) | .443 |
| MFI CD169, median (IQR) | 512.5 (308–738) | 775 (217–7765) | .218 |
| IL-6 (pg/mg protein), median (IQR) | 218.25 (60.27–378.63) | 375.51 (34.7–1689.95) | .218 |
| IL-17 (pg/mg protein), median (IQR) | 7.8 (3.83–29.31) | 6.1 (1.86–27.17) | .467 |
| CD4 T-cells (cells/μL), median (IQR) | 40 (14–102) | 11 (4–70) | .018 |
| Foxp3+ CD25+/CD4 (%), median (IQR) | 17.8 (6.71–28.13) | 16.93 (4.5–81.4) | .654 |
| Caspase 3 (ng/mg protein), median (IQR) | 1.4 (0.56–5.33) | 0.77 (0.14–2.91) | .117 |
| SP-A (ng/mg protein), mean (±SD) | 13.76 (±4.0) | 14.7 (±5.5) | .701 |
MFI: mean fluorescence intensity.